| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | KIP1; MEN4; CDKN4; MEN1B; P27KIP1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CDKN1B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDKN1B抗体的3篇参考文献，包括文献名称、作者和摘要内容概括：
1. **"p27Kip1: A Key Mediator of Cell Cycle Exit"**
*作者：James A. DeCaprio*
**摘要**：该综述总结了p27Kip1(CDKN1B编码蛋白)在细胞周期调控中的作用，重点讨论了其通过抑制CDK复合物诱导细胞周期停滞的机制。文中提到使用特异性CDKN1B抗体通过免疫印迹和免疫组化技术，验证了p27在不同肿瘤组织中的表达缺失与预后的关联。
2. **"Prognostic Significance of p27Kip1 Expression in Breast Cancer"**
*作者：Massimo Mottolese 等*
**摘要**：研究通过免疫组化(使用CDKN1B单克隆抗体)分析了乳腺癌组织中p27蛋白的表达水平，发现低表达与肿瘤高分级、转移风险增加相关，提示p27可作为乳腺癌预后的独立生物标志物。
3. **"CDKN1B/p27 Loss Promotes Tumor Metastasis in Mouse Models"**
*作者：Andrew Koff 等*
**摘要**：利用基因敲除小鼠模型和CDKN1B抗体进行蛋白检测，研究发现p27的缺失通过激活RhoA信号通路促进肿瘤细胞侵袭和转移，揭示了p27在抑制转移中的新机制。
这些文献均涉及CDKN1B抗体的实验应用(如Western blot、免疫组化)，并探讨了其在细胞周期调控及癌症中的功能与临床意义。
CDKN1B (Cyclin-Dependent Kinase Inhibitor 1B), also known as p27Kip1. is a critical regulator of the cell cycle that inhibits cyclin-dependent kinase (CDK) complexes, thereby preventing G1-to-S phase progression. As a tumor suppressor, it plays a pivotal role in maintaining cellular quiescence, differentiation, and apoptosis. Dysregulation of CDKN1B expression or function is frequently associated with cancer development, including breast, prostate, and colorectal cancers, where reduced p27Kip1 levels often correlate with poor prognosis.
CDKN1B antibodies are essential tools for studying its expression, localization, and interactions in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels in tissues or cell lines. Researchers also employ them to investigate post-translational modifications (e.g., phosphorylation at Thr187 or Tyr88) that regulate p27Kip1 stability, subcellular distribution, and proteasomal degradation.
The development of CDKN1B antibodies has advanced understanding of its dual roles: nuclear p27Kip1 enforces cell cycle arrest, while cytoplasmic accumulation in cancers may promote oncogenic signaling. Challenges include ensuring specificity due to homology with other CDK inhibitors (e.g., p21). Validated antibodies are crucial for diagnostic applications, such as stratifying cancer subtypes, and preclinical studies targeting CDKN1B pathways for therapeutic intervention.
×
